Arcellx, Inc. Arcellx, Inc.

Arcellx, Inc.

ACLX

Clasificación en acciones #2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Precio por acción
$115.07
Última sincronización: 2026-05-15
Capitalización bursátil
$6.73B
Cambio (1 día)
0.00%
Cambio (1 año)
34.40%
País
US
Comercio Arcellx, Inc. (ACLX)

Categoría

Healthcare
Historial de desdoblamientos de acciones de Arcellx, Inc. (ACLX)
La acción Arcellx, Inc. (símbolo: ACLX) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción ACLX comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones ACLX.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL